This page ranks diagnostic methods and biomarkers for neurodegenerative diseases by their sensitivity, specificity, and clinical utility. [1]
| Rank | Biomarker | Sensitivity | Specificity | Clinical Use | [2]
|------|-----------|--------------|-------------|--------------| [3]
| 1 | Amyloid PET (Pittsburgh) | 90% | 85% | Confirmed AD |
| 2 | CSF p-tau181 | 85% | 85% | Screening |
| 3 | CSF t-tau | 80% | 75% | Supportive |
| 4 | FDG-PET | 75% | 70% | Differential |
| 5 | Volumetric MRI | 70% | 65% | Staging |
| Rank | Biomarker | Sensitivity | Specificity | Status |
|---|---|---|---|---|
| 1 | Plasma p-tau181 | 85% | 85% | Clinical |
| 2 | Plasma p-tau217 | 90% | 85% | Clinical |
| 3 | Plasma p-tau231 | 80% | 80% | Clinical |
| 4 | Plasma GFAP | 75% | 70% | Research |
| 5 | Plasma NFL | 70% | 65% | Research |
| Rank | Method | Sensitivity | Specificity | Notes |
|---|---|---|---|---|
| 1 | DaTscan (DAT SPECT) | 80% | 85% | FDA approved |
| 2 | MIBG myocardial scintigraphy | 75% | 80% | Japan approved |
| 3 | Olfactory testing | 70% | 65% | Screening |
| 4 | Autonomic testing | 65% | 70% | Research |
| 5 | Sleep study (RBD) | 60% | 60% | Early marker |
| Rank | Biomarker | Sensitivity | Specificity | Status |
|---|---|---|---|---|
| 1 | Alpha-synuclein RT-QuIC (CSF) | 85% | 90% | Clinical |
| 2 | Alpha-synuclein Seed Amplification | 80% | 90% | Research |
| 3 | PlasmaNfL | 70% | 65% | Research |
| 4 | Skin biopsy | 75% | 80% | Clinical |
| Rank | Method | Sensitivity | Specificity | Use |
|---|---|---|---|---|
| 1 | EMG | 95% | 80% | Gold standard |
| 2 | Nerve conduction studies | 70% | 90% | Standard |
| 3 | MRI | 60% | 85% | Differential |
| 4 | CSF biomarkers | 65% | 70% | Research |
| 5 | Genetic testing | 70% | 100% | Confirmatory |
| Rank | Method | Sensitivity | Specificity | Notes |
|---|---|---|---|---|
| 1 | FDG-PET | 75% | 80% | Key tool |
| 2 | MRI (atrophy pattern) | 70% | 75% | Standard |
| 3 | CSF (progranulin) | 60% | 95% | Genetic |
| 4 | Neuropsych testing | 80% | 60% | Screening |
The 2017 DLB consensus criteria provide the framework for diagnosis[1:1][2:1]:
| Rank | Feature | Sensitivity | Specificity | Clinical Use |
|---|---|---|---|---|
| 1 | Core clinical features | Variable | Variable | Foundation |
| 2 | Suggestive features | Variable | Variable | Supportive |
| 3 | Indicative biomarkers | Variable | Variable | Confirmation |
| Feature | Sensitivity | Specificity |
|---|---|---|
| Visual hallucinations | 60-80% | 70-90% |
| Spontaneous parkinsonism | 50-70% | 80-90% |
| Cognitive fluctuation | 50-70% | 70-85% |
| REM sleep behavior disorder | 50-80% | 80-90% |
| Rank | Biomarker | Sensitivity | Specificity | Status |
|---|---|---|---|---|
| 1 | DaTscan (DAT SPECT) | 75-85% | 85-90% | FDA approved |
| 2 | CSF alpha-synuclein RT-QuIC | 85-95% | 80-90% | Clinical |
| 3 | Polysomnography (RBD) | 80-90% | 80-90% | Clinical |
| 4 | Olfactory testing | 60-70% | 65-75% | Screening |
| 5 | MIBG scintigraphy | 70-80% | 75-85% | Japan approved |
DaTscan is a key imaging biomarker for DLB[3:1]:
RBD is a strong prodromal marker for DLB[4]:
Olfactory dysfunction is common in DLB:
Seed amplification assays represent a breakthrough[5]:
| Feature | DLB | AD | PDD |
|---|---|---|---|
| Visual hallucinations early | +++ | + | ++ |
| Parkinsonism | +++ | - | +++ |
| DaTscan abnormal | +++ | - | +++ |
| RBD | +++ | - | +++ |
| Memory prominent early | + | +++ | + |
| Feature | AD | FTD | DLB |
|---|---|---|---|
| Memory early | +++ | + | ++ |
| Language early | + | +++ | + |
| Visual hallucinations | + | + | +++ |
| Parkinsonism | + | + | +++ |
| Fluctuation | - | - | +++ |
| Rank | Biomarker | Sensitivity | Specificity | Clinical Use |
|---|---|---|---|---|
| 1 | MRI (midbrain atrophy, HCT) | 80% | 85% | Standard |
| 2 | Tau PET (Flortaucipir) | 75% | 80% | Emerging |
| 3 | CSF p-tau181 | 65% | 75% | Research |
| 4 | FDG-PET (pattern) | 70% | 75% | Differential |
| 5 | DaTscan | 50% | 60% | Limited |
| Rank | Biomarker | Sensitivity | Specificity | Clinical Use |
|---|---|---|---|---|
| 1 | MRI (asymmetric atrophy) | 75% | 70% | Standard |
| 2 | Tau PET | 65% | 75% | Emerging |
| 3 | FDG-PET (pattern) | 70% | 70% | Differential |
| 4 | CSF biomarkers | 60% | 70% | Research |
| 5 | DaTscan | 55% | 65% | Limited |
| Disease | Key Features | Tau Isoforms |
|---|---|---|
| PSP | Vertical gaze palsy, falls | 4R |
| CBS | Asymmetric rigidity, apraxia | 4R |
| AGD | Argyrophilic grains | 4R |
| CBD | Cortical dysfunction | 4R |
| Factor | Importance |
|---|---|
| Accessibility | Blood > CSF > Imaging |
| Cost | Genetic < Blood < CSF < PET |
| Invasiveness | Clinical > Imaging > Blood |
| Turnaround time | Hours to weeks |
The current Diagnostic Accuracy Rankings covers major diseases but has significant gaps:
Multiple System Atrophy (MSA) — No dedicated MSA diagnostic section:
Dementia with Lewy Bodies (DLB) — Only mentioned in differential, needs dedicated section:
Vascular Dementia — Absent from rankings:
Creutzfeldt-Jakob Disease (CJD) — Not covered:
Huntington's Disease — Missing diagnostics:
Genetic Testing Coverage — Limited:
Blood-Based Biomarkers — Need more comprehensive coverage:
-NfL across diseases
Digital Biomarkers — Absent:
Priority gaps to address:
Jack CR, et al. NIA-AA Research Framework. Alzheimer's Dement. 2023. 2023. ↩︎ ↩︎
Postuma RB, et al. MDS research criteria. Mov Disord. 2015. 2015. ↩︎ ↩︎
Hansson O, et al. Blood biomarkers. Nat Rev Neurol. 2024. 2024. ↩︎ ↩︎
CSF RT-QuIC in DLB. 2023. ↩︎